In 2019, Morgenroth et al. demonstrated for the first time in vitro and in vivo the potential of targeting neovasculature-associated PSMA by radiolabelled PSMA-targeting radiopharmaceuticals as a potential therapeutic option in TN BC mice [33]. This evidence concerns the gene FOLH1 and breast cancer.